

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.  
Petitioner

v.

POZEN INC. and HORIZON PHARMA USA, INC.  
Patent Owners

---

Case No. IPR2018-00272  
Patent No. 9,393,208

---

**PATENT OWNER'S EXHIBIT LIST**

**PATENT OWNER'S EXHIBIT LIST**

<b>Exhibit No.</b>	<b>Description of Document</b>
2001	Gabriel, S.E., et al., "Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs," <i>Annals of Internal Medicine</i> , Vol. 115, No. 10, pp. 787-796 (1991) ("Gabriel")
2002	Cryer, B. and Feldman, M., "Effects of Nonsteroidal Anti-inflammatory Drugs on Endogenous Gastrointestinal Prostaglandins and Therapeutic Strategies for Prevention and Treatment of Nonsteroidal Anti-inflammatory Drug-Induced Damage," <i>Archives of Internal Medicine</i> , Vol. 152, pp. 1145-1155 (1992) ("Cryer")
2003	Fries, J.F., et al., "Nonsteroidal Anti-Inflammatory Drug-Associated Gastropathy: Incidence and Risk Factor Models," <i>The American Journal of Medicine</i> , Vol. 91, pp. 213-222 (1991) ("Fries")
2004	U.S. Patent No. 9,220,698 Prosecution History Excerpt: Response to Final Office Action Mailed March 26, 2015 (Sept. 25, 2015)
2005	U.S. Patent No. 9,220,698 Prosecution History Excerpt: Advisory Action (Oct. 9, 2015)
2006-2072	Exhibits Not Used
2073	Opinion & Order, filed on November 14, 2017 in <i>Horizon Pharma, Inc. v. Dr. Reddy's Laboratories, Inc.</i> , Civ. A. No. 2:15-cv-03324-SRC-CLW (SRC)
2074	Memorandum of Mylan and DRL in Support of Their Motion for Summary Judgment of Invalidity of U.S. Patent Nos. 9,220,698 and 9,393,208, filed on November 12, 2018 in <i>Horizon Pharma, Inc. v. Dr. Reddy's Laboratories, Inc.</i> , Civ. A. No. 2:15-cv-03324-SRC-CLW (SRC)
2075	Opinion, filed on November 19, 2018 in <i>Horizon Pharma, Inc. v. Dr. Reddy's Laboratories, Inc.</i> , Civ. A. No. 2:15-cv-03324-SRC-CLW (SRC)
2076	Final Judgment Under Rule 54(b), signed and filed January 22, 2019 in <i>Horizon Pharma, Inc. v. Dr. Reddy's Laboratories, Inc.</i> , Civ. A. No. 2:15-cv-03324-SRC-CLW (SRC)
2077	Final Judgment Under Rule 54(b), signed and filed January 22, 2019 in <i>Horizon Pharma, Inc. v. Dr. Reddy's Laboratories, Inc.</i> , Civ. A. No. 2:15-cv-03324-SRC-CLW (SRC)

Date: February 8, 2019

Respectfully submitted,

By: *Thomas A. Blinka*  
Thomas A. Blinka  
Reg. No. 44,541  
Counsel for Patent Owner

COOLEY LLP  
ATTN: Patent Group  
1299 Pennsylvania Avenue,  
N.W Suite 700  
Washington, DC 20004-2400  
Tel: 720-566-4119  
Fax: 720-566-4099

**CERTIFICATE OF SERVICE UNDER 37 C.F.R. § 42.6(e)**

I, Thomas A. Blinka, hereby certify that on this 8th day of February, 2019,  
the foregoing **Patent Owner's Exhibit List** was served electronically via email on  
the following:

Brandon M. White  
[bmwhite@perkinscoie.com](mailto:bmwhite@perkinscoie.com)  
700 13<sup>th</sup> St., NW Suite 600  
Washington, DC 20005

Emily Greb  
[egreb@perkinscoie.com](mailto:egreb@perkinscoie.com)  
One East Main St., Suite 201  
Madison, WI 53703

[EsoNaproxen@perkinscoie.com](mailto:EsoNaproxen@perkinscoie.com)

Date: February 8, 2019

By: /Thomas A. Blinka/  
Thomas A. Blinka  
Reg. No. 44,541  
Counsel for Patent Owner